Hexocyclium
Tral (hexocyclium) is a small molecule pharmaceutical. Hexocyclium was first approved as Tral on 1982-01-01. It is known to target muscarinic acetylcholine receptor M3, muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M4, and muscarinic acetylcholine receptor M1.
Trade Name | Tral |
---|---|
Common Name | Hexocyclium |
Indication | |
Drug Class | Quaternary ammonium derivatives |